Anchored in work that seems to have been undertaken by the principals and subsequently licensed from Washington University, Pacific Northwest Biotechnology (PNB) was established as a biopharmaceutical company organized around commercializing technology based on a unique ligand/receptor discovery platform. At the time of their SBIR Involvement, the company had a late pre-clinical stage small molecule with a demonstrated efficacy in animal models of breast, melanoma and anti-metastasis. PNB had other molecules in its patented library with clinical indications that have potentially large markets. The intent had been to monetize its drug pipeline in a manner that would enable the firm to manufacture/bring to market one/more of the most promising drugs in the pipeline. Market conditons of the period (2001-2010) made that difficult and the firm seems to have ceased operations c. 2013
